Abstract
Early growth response (EGR) proteins have been reported to be involved in cell growth and apoptosis in a variety of cancer types and could inhibit tumor development. However, the role of EGR1/2 in papillary thyroid carcinoma (PTC) has not been elucidated. The expression pattern of EGR1/2 in adjacent tissues and cancer tissues and the clinical prognosis of EGR1/2 were analyzed by using the samples from TCGA database. The cell viability was detected by MTT assay. Luciferase reporter assay was used to demonstrate the binding of EGR1/2 to the target gene promotor region. Our results showed that EGR1/2 was significantly downregulated in tumor tissues and correlated with poor prognosis. Overexpression of EGR1/2 inhibited proliferation of IHH-4 and BCPAP cells, and knockdown of EGR1/2 showed a reverse effect. Overexpression of EGR1 or EGR2 promoted phosphatase and tension homolog (PTEN) or Bcl-2-associated X (BAX) expression, and EGR1 or EGR2 was able to directly bind to the promoter region of PTEN or BAX. In conclusion, we found that the altered expression of EGR1/2 affected the proliferation of PTC cells and regulated the expression of PTEN and BAX.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bhattacharyya S, Fang F, Tourtellotte W, Varga J (2013) Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). J Pathol 229:286–297. https://doi.org/10.1002/path.4131
Cabanillas ME, McFadden DG, Durante C (2016) Thyroid cancer. Lancet 388:2783–2795. https://doi.org/10.1016/S0140-6736(16)30172-6
Cerami E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095
Chen DG et al (2017) Inhibition of EGR1 inhibits glioma proliferation by targeting CCND1 promoter. J Exp Clin Cancer Res 36:186. https://doi.org/10.1186/s13046-017-0656-4
Cui J, Placzek WJ (2018) Post-transcriptional regulation of anti-apoptotic BCL2 family members. Int J Mol Sci. https://doi.org/10.3390/ijms19010308
Gao J et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:1. https://doi.org/10.1126/scisignal.2004088
Gomez-Martin D, Diaz-Zamudio M, Galindo-Campos M, Alcocer-Varela J (2010) Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun Rev 9:454–458. https://doi.org/10.1016/j.autrev.2009.12.006
Grewal RK, Ho A, Schoder H (2016) Novel approaches to thyroid cancer treatment and response assessment. Semin Nucl Med 46:109–118. https://doi.org/10.1053/j.semnuclmed.2015.10.010
Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE (2014) PTEN function: the long and the short of it. Trends Biochem Sci 39:183–190. https://doi.org/10.1016/j.tibs.2014.02.006
Kang HS, Ock J, Lee HJ, Lee YJ, Kwon BM, Hong SH (2013) Early growth response protein 1 upregulation and nuclear translocation by 2’-benzoyloxycinnamaldehyde induces prostate cancer cell death. Cancer Lett 329:217–227. https://doi.org/10.1016/j.canlet.2012.11.006
Kim J et al (2014) EGR1-dependent PTEN upregulation by 2-benzoyloxycinnamaldehyde attenuates cell invasion and EMT in colon cancer. Cancer Lett 349:35–44. https://doi.org/10.1016/j.canlet.2014.03.025
Kouniavsky G, Zeiger MA (2010) Thyroid tumorigenesis and molecular markers in thyroid cancer. Curr Opin Oncol 22:23–29. https://doi.org/10.1097/CCO.0b013e328333846f
Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B, Vallette FM (2007) Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12:887–896. https://doi.org/10.1007/s10495-007-0749-1
Lin HY, Glinsky GV, Mousa SA, Davis PJ (2015) Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget 6:14735–14743. https://doi.org/10.18632/oncotarget.4023
Liu D, Yang C, Bojdani E, Murugan AK, Xing M (2013) Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst 105:1617–1627. https://doi.org/10.1093/jnci/djt249
LiVolsi VA (2011) Papillary thyroid carcinoma: an update. Mod Pathol 24(Suppl 2):S1-9. https://doi.org/10.1038/modpathol.2010.129
Lu L et al (2018) Egr2 enhances insulin resistance via JAK2/STAT3/SOCS-1 pathway in HepG2 cells treated with palmitate. Gen Comp Endocrinol 260:25–31. https://doi.org/10.1016/j.ygcen.2017.08.023
Narayanan S, Colevas AD (2016) Current standards in treatment of radioiodine refractory thyroid cancer. Curr Treat Options Oncol 17:30. https://doi.org/10.1007/s11864-016-0404-6
Novosel I, Bulimbasic S, Ramljak V, Matkovic B, Dosen D, Separovic V (2006) p53, bcl-2 and Ki-67 in the diagnosis of insular thyroid gland cancer. Case report with a review of literature. Lijec Vjesn 128:264–267
Osamura R, Grossman A, Korbonits M, Kovacs K, Lopes M, Matsuno A, Trouillas J (2017) WHO classification of tumours of endocrine organs. IARC Lyon, France
Petersohn D, Thiel G (1996) Role of zinc-finger proteins Sp1 and zif268/egr-1 in transcriptional regulation of the human synaptobrevin II gene. Eur J Biochem 239:827–834. https://doi.org/10.1111/j.1432-1033.1996.0827u.x
Roman BR, Morris LG, Davies L (2017) The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes 24:332–336. https://doi.org/10.1097/MED.0000000000000359
Santino P, Martignani E, Miretti S, Baratta M, Accornero P (2017) Mechanisms of modulation of the Egr gene family in mammary epithelial cells of different species. Gen Comp Endocrinol 247:87–96. https://doi.org/10.1016/j.ygcen.2017.01.020
Sherman SI (2003) Thyroid carcinoma. Lancet 361:501–511. https://doi.org/10.1016/s0140-6736(03)12488-9
Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13:283–296. https://doi.org/10.1038/nrm3330
Sukhatme VP (1991) The Egr family of nuclear signal transducers. Am J Kidney Dis 17:615–618. https://doi.org/10.1016/s0272-6386(12)80333-7
Sun Z et al (2019) EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity. Nat Commun 10:3892. https://doi.org/10.1038/s41467-019-11905-3
Unoki M, Nakamura Y (2003) EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene 22:2172–2185. https://doi.org/10.1038/sj.onc.1206222
Wang Y, Chen Z (2020) Mutation detection and molecular targeted tumor therapies. STEMedicine 1:e11. https://doi.org/10.37175/stemedicine.v1i1.11
Worby CA, Dixon JE (2014) Pten. Annu Rev Biochem 83:641–669. https://doi.org/10.1146/annurev-biochem-082411-113907
Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184–199. https://doi.org/10.1038/nrc3431
Xing M (2019) Genetic-guided risk assessment and management of thyroid cancer. Endocrinol Metab Clin N Am 48:109–124. https://doi.org/10.1016/j.ecl.2018.11.007
Yang Y et al (2019) EGR1 interacts with DNMT3L to inhibit the transcription of miR-195 and plays an anti-apoptotic role in the development of gastric cancer. J Cell Mol Med. https://doi.org/10.1111/jcmm.14597
Young E et al (2017) EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia 31:1547–1554. https://doi.org/10.1038/leu.2016.359
Zeng XR, Sun Y, Wenger L, Cheung HS (2005) Basic calcium phosphate crystal-induced Egr-1 expression stimulates mitogenesis in human fibroblasts. Biochem Biophys Res Commun 330:658–664. https://doi.org/10.1016/j.bbrc.2005.03.036
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical Approval
The study does not contain any experiments on human or animals.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Guo, H., Zhang, L. EGR1/2 Inhibits Papillary Thyroid Carcinoma Cell Growth by Suppressing the Expression of PTEN and BAX. Biochem Genet 59, 1544–1557 (2021). https://doi.org/10.1007/s10528-021-10075-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-021-10075-6